MX354302B - Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montaña por falta de oxigeno y presion de aire reducida. - Google Patents

Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montaña por falta de oxigeno y presion de aire reducida.

Info

Publication number
MX354302B
MX354302B MX2014015048A MX2014015048A MX354302B MX 354302 B MX354302 B MX 354302B MX 2014015048 A MX2014015048 A MX 2014015048A MX 2014015048 A MX2014015048 A MX 2014015048A MX 354302 B MX354302 B MX 354302B
Authority
MX
Mexico
Prior art keywords
sub
treatment
lack
oxygen
pharmaceutical composition
Prior art date
Application number
MX2014015048A
Other languages
English (en)
Spanish (es)
Other versions
MX2014015048A (es
Inventor
Fischer Bernhard
Lucas Rudolf
Fischer Hendrik
Original Assignee
Apeptico Forschung & Entwicklung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX354302(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apeptico Forschung & Entwicklung Gmbh filed Critical Apeptico Forschung & Entwicklung Gmbh
Publication of MX2014015048A publication Critical patent/MX2014015048A/es
Publication of MX354302B publication Critical patent/MX354302B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2014015048A 2012-06-28 2013-06-19 Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montaña por falta de oxigeno y presion de aire reducida. MX354302B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12173983.3A EP2679239A1 (de) 2012-06-28 2012-06-28 Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
PCT/EP2013/062777 WO2014001177A1 (de) 2012-06-28 2013-06-19 Pharmazeutische zusammensetzung zur behandlung der durch sauerstoffarmut und verringerten luftdruck vermittelten pulmonalen form der höhenkrankheit

Publications (2)

Publication Number Publication Date
MX2014015048A MX2014015048A (es) 2015-06-05
MX354302B true MX354302B (es) 2018-02-23

Family

ID=48672620

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015048A MX354302B (es) 2012-06-28 2013-06-19 Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montaña por falta de oxigeno y presion de aire reducida.

Country Status (14)

Country Link
US (2) US9802985B2 (enExample)
EP (2) EP2679239A1 (enExample)
JP (1) JP6113277B2 (enExample)
KR (1) KR102010793B1 (enExample)
CN (1) CN104427993B (enExample)
AP (1) AP2014008162A0 (enExample)
AU (1) AU2013283563B2 (enExample)
CA (1) CA2875749C (enExample)
EA (1) EA030384B1 (enExample)
ES (1) ES2602197T3 (enExample)
IN (1) IN2015DN00585A (enExample)
MX (1) MX354302B (enExample)
PE (1) PE20150198A1 (enExample)
WO (1) WO2014001177A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2791225T3 (es) * 2014-03-04 2020-11-03 Apeptico Forschung & Entwicklung Gmbh Atenuación de la inflamación intrapulmonar
WO2015140125A2 (en) * 2014-03-18 2015-09-24 Apeptico Forschung Und Entwicklung Gmbh Dry-powder peptide medicament
EP3365275A4 (en) 2015-08-25 2019-06-26 Bar-Ilan University ASYMMETRIC ELECTROCHEMICAL CELL DEVICE AND METHOD OF OPERATING THE SAME
CA3063524A1 (en) 2017-05-19 2018-11-22 Trudell Medical International Positive expiratory pressure device
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud
EP4051311A4 (en) * 2019-10-29 2023-12-06 University of Pittsburgh - of the Commonwealth System of Higher Education LUNG-SPECIFIC TARGETING PEPTIDE (LTP), COMPOSITIONS AND RELATED USES
CN115461356A (zh) 2020-05-08 2022-12-09 阿佩普蒂科研究和开发有限责任公司 用于预防或治疗covid-19的肽
KR20250164550A (ko) 2024-05-16 2025-11-25 장태현 고산병 예방을 위한 입술용 화장료 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
CA2155103A1 (en) 1993-02-03 1994-08-18 Rudolph Lucas Tnf-alpha muteins and a process for preparing them
JP4542266B2 (ja) 1998-08-14 2010-09-08 ルドルフ・ルカス 浮腫の治療に使用されるｔｎｆ由来のペプチド
WO2006013183A1 (en) * 2004-08-06 2006-02-09 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
MX2011009251A (es) * 2009-03-04 2011-11-18 Mannkind Corp Sistema mejorado de suministro de farmaco en polvo seco.
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
AT510585B1 (de) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase

Also Published As

Publication number Publication date
EA030384B1 (ru) 2018-07-31
KR20150037815A (ko) 2015-04-08
EA201500061A1 (ru) 2015-06-30
CN104427993B (zh) 2017-03-08
US9802985B2 (en) 2017-10-31
ES2602197T3 (es) 2017-02-20
CA2875749A1 (en) 2014-01-03
AU2013283563B2 (en) 2017-06-08
JP2015526399A (ja) 2015-09-10
JP6113277B2 (ja) 2017-04-12
MX2014015048A (es) 2015-06-05
PE20150198A1 (es) 2015-02-19
EP2866824B1 (de) 2016-08-10
KR102010793B1 (ko) 2019-08-14
US20150225460A1 (en) 2015-08-13
US20190211061A1 (en) 2019-07-11
WO2014001177A1 (de) 2014-01-03
CN104427993A (zh) 2015-03-18
AP2014008162A0 (en) 2014-12-31
IN2015DN00585A (enExample) 2015-06-26
EP2679239A1 (de) 2014-01-01
CA2875749C (en) 2019-02-26
AU2013283563A1 (en) 2015-01-15
EP2866824A1 (de) 2015-05-06

Similar Documents

Publication Publication Date Title
MX354302B (es) Composicion farmaceutica para el tratamiento de la forma pulmonar de mal de montaña por falta de oxigeno y presion de aire reducida.
MX341324B (es) Polipeptidos.
NZ606250A (en) Methods of inhibition of protein fucosylation in vivo using fucose analogs
MY162324A (en) Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
MX2013001677A (es) Formulaciones estables de linaclotida.
NZ601374A (en) Stabilized antibody-containing liquid formulations
MX345501B (es) Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
EP4234698A3 (en) Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
WO2010085700A3 (en) Treatment for obesity
GB2502716A (en) Fluorocarbon-linked peptide formulation
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
MX2012008413A (es) Composicion novedosa de retigabina.
IN2014DN06920A (enExample)
WO2010118291A3 (en) Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
PH12012501340A1 (en) Composition for improving brain function and method for improving brain function
NZ596501A (en) Casb7439 constructs
WO2011143280A3 (en) Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling
NZ732301A (en) Peptide compound, preparation method therefor, and application thereof
WO2010118286A3 (en) Benzimidazole modulators of h1 receptor and/or ns4b protein activity
PH12012502198A1 (en) Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
WO2012102625A3 (en) Therapeutic composition
PH12013500945A1 (en) Crystalline forms of an alkoxymidazol-1-ylmethyl-biphenyl carboxylic acid
WO2012064306A3 (en) Effervescent formulations of rosuvastatin
WO2012047007A3 (ko) 손톱 또는 발톱 성장 촉진용 조성물
MY161665A (en) Formulations for bovine granulocyte colony stimulating factor and variants thereof

Legal Events

Date Code Title Description
FG Grant or registration